Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. - Wikidata - wikimedia - TriplyDB

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

http://www.wikidata.org/entity/Q37578128

about

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting Psoriasis: from pathogenesis to novel therapeutic approaches.New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.Briakinumab for the treatment of plaque psoriasis.Biological therapies for psoriasis.

P2860

Q34112840-5F8BFD9E-C60A-40D2-8142-D16B4BD173C5 Q34377347-6BE59509-2E0C-4877-9FA0-C5B3179E2B0A Q37789387-9192E066-4EF7-4456-988A-AD6F910AE3E3 Q37846678-26626EF4-12DF-45A1-B79A-EFCFC2874D20 Q37955218-A616A073-21C3-4ED7-A105-7AB53224268F Q38155648-DEF5BB78-D1A4-4B39-8CAD-2F2937A09290

P2860

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

http://www.wikidata.org/entity/Q37578128

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

@en

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

@nl

type

label

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

@en

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

@nl

prefLabel

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

@en

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

@nl

P1433

Q37578128-152B686A-8F08-480A-AFD1-01E34AABC614

P1476

Q37578128-ADDA333E-AC5A-4AF6-B07E-22CB887070A5

P2093

Q37578128-1CA3FAE0-6578-49A8-BFC5-0F0E89D1BF9F

Q37578128-BAA2CC62-2C25-4690-9FDA-6C62DE84D4A7

Q37578128-CF5A6D72-A213-47E1-BDF8-B9843BD394F9

P2860

Q37578128-0214A45B-F42B-4086-870F-8FF75C32C216

Q37578128-155A4B21-88E3-496B-9686-79C568591018

Q37578128-21464B11-EEBE-4993-9D97-88EA38595D27

Q37578128-241F7817-FDA4-473E-A3F0-7D64E54BAABD

Q37578128-33E5BB78-893A-41D1-BAE9-C8C915A49D9C

Q37578128-4681330D-563D-411D-9878-1FE98AAE0F88

Q37578128-50E2711C-F676-42E7-A347-FA5A44F5BB24

Q37578128-53571884-475F-4666-8AD2-827AE0E17101

Q37578128-6341E979-A334-46E7-85C5-EC09B1E87729

Q37578128-63CC9C45-F195-4C38-AA39-802260C75460

P304

Q37578128-033F811B-BA0E-4052-9F96-EADDD70D81A7

P31

Q37578128-E2FB98EA-FE7A-4A35-BA5D-1DDD5254F535

P356

Q37578128-A94F8DB1-10FE-49ED-A163-9694B0D7C9E4

P407

Q37578128-1F029F44-E0C0-49E0-89CB-362032B9DE6B

P433

Q37578128-1111F578-6018-4FB0-AE47-65C05BA32ED8

P478

Q37578128-FF53BBED-CC05-4C81-9410-2EB9436DA2A3

P50

Q37578128-9279BB8E-90C8-4CCD-BA1F-3E7FE43CC993

P577

Q37578128-B25E4EDC-BA56-4401-91E0-A76FECDCE40B

P5875

Q37578128-6FE8E81B-284E-4202-913E-71E6980ECFA9

P698

Q37578128-2A8C0F65-A52E-4A91-A5BF-A2AFEE09A010

P356

P1433

Annals of Pharmacotherapy

P1476

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis

@en

P2093

Benjamin P Exter

http://www.w3.org/2001/XMLSchema#string

James V Scanlon

http://www.w3.org/2001/XMLSchema#string

Michael Steinberg

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality.

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

IL-12 and IL-23: master regulators of innate and adaptive immunity.

P304

1456-1465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1M151

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

Courtney I Jarvis

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733310

http://www.w3.org/2001/XMLSchema#string

P698

19671802

http://www.w3.org/2001/XMLSchema#string